[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-asthma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,80,107,136,161,197,222,251,276,297,325,350,376],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100627825","humidity-asthma-interventions-for-low-socioeconomic-status-children-100627825",false,"NCT07453667","Humidity Asthma Interventions for Low Socioeconomic Status Children","Novel Strategies to Improve Housing Quality and Respiratory Health for Low Socioeconomic Status Children With Asthma","INHALE","Inclusion Criteria:\n\n* Documented diagnosis of asthma by one child (\\\u003C 18 years of age) living within the home\n* Parent\u002Fguardian able to complete informed consent\n* Residence within the City of Cleveland or immediate suburbs (e.g., East Cleveland, Garfield Heights, Warrensville Heights, Parma, Brook Park, Brooklyn\u002FOld Brooklyn)\n\nExclusion Criteria:\n\n* \\> 18 years of age\n* Rental property with landlord unwilling or unable to give consent for remediation","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this intervention study is to assess the effectiveness of low-cost humidity and mold reduction interventions in the home for reducing pediatric asthma. The study will have two groups, a treatment group that receives the healthy home interventions during the study and a second control group that will receive these after the study. We will compare pediatric asthma before and three months after the healthy home interventions are performed.",[27],"Pediatric Asthma",[29,30,31,32,33,34],"asthma","environmental health","indoor air quality","endotoxin","mold","humidity","RECRUITING","2026-06-02",{"date":38,"type":39},"2026-06-03","ACTUAL",{"date":41,"type":39},"2026-05-02",{"date":43,"type":21},"2027-05",{"name":45,"class":46},"Case Western Reserve University","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100585556","social-needs-screening-and-chronic-diseases-study-we-care-100585556","NCT06903897","Social Needs Screening and Chronic Diseases Study (WE CARE)","Improving Chronic Disease Outcomes Across the Lifespan by Addressing Structural Racism","Inclusion Criteria:\n\n* Adults and children with diagnosed chronic diseases (hypertension, diabetes mellitus, hyperlipidemia, asthma, or depression) who receive Family Medicine care at one of the study sites.\n* Children (\\\u003C18 years of age) with a diagnosis of asthma.\n* Adult patients (18 years or older) with a diagnosis of diabetes mellitus, hypertension, hyperlipidemia and\u002For depression.\n\nExclusion Criteria:\n\n* In adults (\\>18 years of age), those without one or more of the following diagnoses as recorded by ICD-10 codes in their EHR: hypertension, hyperlipidemia, diabetes mellitus, or depression.\n* In children (\\\u003C18 years of age), those without a diagnosis of asthma.",true,{"count":57,"type":21},68000,[24],"The goal of this clinical trial is to learn if the implementation of the WE CARE social determinants of health (SDOH) screening and referral intervention with an antiracist lens in primary care settings can lead to a meaningful decrease in chronic disease by monitoring conditions such as hypertension, diabetes, depression, hyperlipidemia, and asthma through clinical measures. The main question it aims to answer is:\n\nDoes the WE CARE SDOH screening and referral intervention applying an antiracism lens informed implementation strategies have the potential to reduce racial\u002Fethnic health inequities in chronic diseases for minoritized patients?",[61,62,63,27,64],"Hyperlipidemias","Diabetes","Depression","Hypertension",[66,67,68,69],"Basic Needs","Social Determinants of Health","Screening tools","Antiracism","2026-05-18",{"date":72,"type":39},"2026-05-22",{"date":74,"type":39},"2025-10-08",{"date":76,"type":21},"2028-09-30",{"name":78,"class":46},"University of Massachusetts, Worcester",3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":79},"100637491","bilevel-positive-airway-pressure-bpap-for-severe-asthma-100637491","NCT07582211","Bilevel Positive Airway Pressure (BPAP) for Severe Asthma","Bilevel Positive Airway Pressure (BPAP) for Severe Asthma Exacerbations: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. 5 to 17 years of age (inclusive) presenting to the ED with an asthma exacerbation.\n2. Demonstrate moderate-severe asthma exacerbation at triage (i.e., receive an institutional asthma score equivalent to moderate-severe asthma exacerbation or a Pediatric Respiratory Assessment Measure (PRAM) score of 6 or above).\n\nExclusion Criteria:\n\n1. Prior participation in the study.\n2. Use of BPAP at any time within approximately 12 hours for this acute asthma exacerbation, including in prehospital, ED, or inpatient settings, prior to randomization.\n3. Receipt of continuous albuterol for over 150 minutes prior to being approached for consent.\n4. If a blood gas is obtained, PaCO2 greater than 60 mmHg on the most recent blood gas prior to being approached for consent.\n\n   Note: Blood gas values are not required for eligibility confirmation.\n5. Anticipated immediate need (i.e., within approximately an hour after completion of first-line therapy) for invasive mechanical ventilation (e.g., endotracheal tube or laryngeal mask airway) or non-invasive mechanical ventilation (e.g., continuous positive airway pressure (CPAP) or BPAP), as determined by the treating physician.\n6. Presence of a tracheostomy or a baseline requirement for noninvasive ventilation.\n7. Wheezing due to non-asthma causes (e.g., foreign body, tracheomalacia, vocal cord dysfunction, pulmonary edema, uncorrected congenital heart disease, cystic fibrosis, or anaphylaxis).\n8. Absolute or relative contraindication to BPAP, defined as any of the following:\n\n   1. Facial trauma within the area where the face mask would be applied for BPAP (excluding minor abrasion or cuts on forehead or skull).\n   2. Uncontrollable vomiting (i.e., \\> 3 episodes within approximately 1 hour prior to being approached for consent).\n   3. Hypotension for age, defined as systolic blood pressure (SBP) less than 70 plus twice the patient's age in years (i.e., SBP \\\u003C 70 + \\[2 x age in years\\]).\n   4. Glasgow Coma Score of 8 or less.\n   5. Known or clinical suspicion for air leak syndrome (e.g., pneumothorax, pneumomediastinum, pneumopericardium, or subcutaneous emphysema).\n9. Weight \\\u003C 20 kg.\n10. Presence of an intra-abdominal mass compressing the stomach (e.g., due to tumor or large volume ascites) through EMR or medical history.\n11. Known or suspected pregnancy by history or if pregnancy test completed by clinical team.\n12. Any medical condition that, in the opinion of a site investigator, could 1) lead to difficulty complying with protocol procedures, 2) interfere with the safe completion of the study, or 3) affect the validity of the endpoint assessments.\n13. PRAM score less than 7 or greater than 10 based on concurrent clinical assessment by a healthcare provider after completion of standard first-line therapies, which is defined as receiving all of the following prior to ED arrival or during the ED encounter for this acute asthma exacerbation:\n\n    1. Albuterol with or without ipratropium bromide, either at least 3 albuterol doses via inhalation method (e.g., metered-dose inhaler (MDI) or nebulized) or at least one hour of continuous albuterol (i.e., continuous nebulized albuterol or three consecutive intermittent nebulized albuterol treatments as bridging therapy).\n    2. Corticosteroids (e.g., Prednisolone, Prednisone, Dexamethasone\u002FDecadron, or Methylprednisolone) via enteral, intravenous, or intramuscular methods.\n\n    Note: Oxygen is not a required first-line therapy.\n14. Do not require continuous albuterol or a second round of albuterol treatments (e.g., three back-to-back treatments or one hour of burst albuterol treatment) following completion of standard first-line therapies.","5 Years","17 Years",{"count":90,"type":21},36,[24],"The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach.\n\nThe main questions it aims to answer are:\n\n1. Can eligible patients be successfully enrolled and complete study procedures across multiple sites?\n2. What safety events occur with early BPAP use in this population?\n3. How do clinical outcomes (such as symptom improvement and need for intensive care) compare between early BPAP and standard care?\n\nResearchers will compare early initiation of BPAP plus standard asthma therapy to standard asthma therapy alone to determine whether early BPAP is a feasible and potentially beneficial treatment strategy.\n\nParticipants will 1) receive standard asthma therapy with or without early BPAP in the ED, 2) be monitored closely during the ED visit and hospitalization, and 3) have clinical data collected from routine care, including asthma severity scores, treatments, and outcomes.\n\nThe study will enroll approximately 36 participants (about 12 per site) across three sites over one year to inform a future multicenter randomized controlled trial.",[27,94,95,96],"Acute Asthma","BiPAP","Non-invasive Positive Pressure Ventilation","NOT_YET_RECRUITING","2026-05-13",{"date":100,"type":39},"2026-05-15",{"date":102,"type":21},"2026-06",{"date":104,"type":21},"2027-08",{"name":106,"class":46},"Columbia University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100585469","towards-digital-management-of-paediatric-asthma-100585469","NCT06902766","Towards Digital Management of Paediatric Asthma","Towards Digital Management of Pediatric Asthma:a Pilot Study","FrenchCare","Inclusion Criteria:\n\n* Aged 4 to 12, whose asthma has been diagnosed by a physician\n* Followed up for their asthma by a pediatrician or pediatric pulmonologist\n* With asthma severity corresponding to GINA grades 2, 3 or 4 (Global Asthma Initiative Guidelines)\n* Whose controller and reliever treatments are administered using pressurized metered-dose inhalers (p-MDIs)\n* With social security\n* Whose parents or legal guardian(s):\n\n  * Have given their written and informed consent for their child's participation and their participation,\n  * Have a smartphone in the household that can download the application and is compatible with it,\n  * Are capable, in the opinion of the investigator, of understanding the use of the mobile application and module FRENCH CARE specifically dedicated to the research and the digital inhalers provided.\n\nNon-inclusion Criteria:\n\n* Patients with another pathology that could interfere with the evaluation of the endpoints (e.g, bronchopulmonary dysplasia, cystic fibrosis, etc.)\n* Patients whose parents or legal representative(s) are, in the opinion of the investigator, unable to understand the purpose of the study and\u002For express their consent.\n* Patients benefiting from State Medical Aid\n\nExclusion Criteria:\n\n\\- Patient who did not use the system within 15 days of the inclusion visit","4 Years","12 Years",{"count":118,"type":21},50,[24],"This pilot study aims to explore whether a digital approach to managing childhood asthma using connected inhalers and video consultations triggered by alerts from these devices - could work as well as standard in-person care. The connected inhalers track when children use their daily prevention medication and their rescue medication for asthma symptoms. If a child misses several days of prevention medication or uses their rescue inhaler frequently, their doctor receives an alert and can schedule a video consultation to adjust their treatment. Fifty children aged 4-12 years with asthma will participate for 8 months, with half using this digital system and half receiving usual care. The study will measure whether this new approach is practical and acceptable to families and doctors, and will look at its effects on asthma control, quality of life, and healthcare use. The results will help design a larger study to fully test if this digital approach could improve asthma care for children.",[27],[123,124,125],"Pediatric asthma","Digital revolution","Digital inhaler","2026-04-30",{"date":128,"type":39},"2026-05-06",{"date":130,"type":39},"2025-11-25",{"date":132,"type":21},"2027-01",{"name":134,"class":46},"Assistance Publique - Hôpitaux de Paris",1,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":55,"sex":17,"minAge":142,"maxAge":88,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":135},"100631427","evaluation-of-the-medentum-diagnostik-platform-for-pediatric-ent-conditions-and-asthma-100631427","NCT07500532","Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma","Inclusion Criteria:\n\n* Age: Patients between the ages of 4 and 17 years (asthma) and 3-17 years (ENT)\n* Diagnosis:\n\n  o Asthma patients: Diagnosed with mild-to-moderate and severe persistent asthma according to Global Initiative for Asthma (GINA) guidelines, with a history of symptoms or exacerbations requiring medical intervention (prior prednisone course and\u002For albuterol for \\>24 hours in context of acute wheezing episode) in the past 12 months. ENT patients: Diagnosed with common ENT conditions such as acute otitis media (AOM) or strep pharyngitis in the prior year. Diagnosis must be based on established clinical guidelines.\n* Technology access: Must have access to a smartphone, tablet, or other device capable of running the Medentum Diagnostik platform app and access to Wifi or cellular service.\n* Care access: Must be receiving routine care from University of Arizona or associated clinics in Arizona and have active health insurance\n* Consent: Must have parental or guardian consent for participation, as well as child assent when appropriate.(all children ≥7 yrs)\n\nExclusion Criteria:\n\n* Other medical conditions: Patients with additional chronic lung diseases (such as cystic fibrosis) requiring complex specialist care will be excluded. cerebral palsy, neurodevelopmental conditions, congenital heart disease. Patients with complex chronic conditions or chronic ENT conditions requiring complex specialist care will be excluded.\n* Recent surgical\u002Fcomplex ENT medical history: Patients who have had tympanostomy tubes or tonsillectomy\u002Fadenoidectomy, patients with chronic ENT conditions including chronic suppurative or serous otitis media\n* Recent medical history: Patients who have experienced severe asthma exacerbations requiring hospitalization or intensive treatment in the past 4 weeks\n* Comorbidities: Patients with speech delays, hearing impairments, or cognitive impairments that may affect their ability to use the Diagnostik platform accurately will be excluded.\n* Non-compliance risk: Patients or families that are unable to follow study instructions, comply with follow-up visits, or properly use the Medentum platform will be excluded.","3 Years",{"count":144,"type":21},84,[24],"This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma and ENT conditions. Participants will be assigned to either home-based use of the Diagnostik platform with telehealth-supported clinician evaluation or standard in-person care.\n\nThe primary objective is to assess agreement between AI-generated diagnoses and clinician diagnoses obtained during study encounters, including telehealth evaluations in the Diagnostik arm and in-person evaluations in the standard-of-care arm. Secondary objectives include evaluating agreement between AI-generated diagnoses and independent research team diagnoses, as well as assessing usability, patient and caregiver satisfaction, healthcare utilization, and clinical outcomes such as asthma control and symptom resolution.\n\nThis study will also evaluate differences in healthcare utilization, including in-person visits, emergency care use, and time to diagnosis and treatment, between study groups.",[148,149,150,27],"Acute Otitis Media (AOM)","Strep Pharyngitis","Asthma Exacerbation","2026-03-25",{"date":153,"type":39},"2026-03-30",{"date":155,"type":39},"2025-10-01",{"date":157,"type":21},"2026-12-01",{"name":159,"class":160},"Medentum Innovations","INDUSTRY",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":173,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":182,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":47},"100622297","modern-technologies-in-lower-respiratory-tract-infections-in-children-100622297","NCT07381790","Modern Technologies in Lower Respiratory Tract Infections in Children","Modern Technologies for Individual Risk Stratification in Infant Lower Respiratory Tract Infections","MoT-LRTI","Inclusion Criteria:\n\n* clinical diagnosis of lower respiratory tract infection\n* with tachypnea and\u002For\n* wheezing\n* Retractions\n* Respiratory difficulties\n\nExclusion Criteria:\n\n* Severe Congenital heart disease (not ASD, small VSD, PDA)\n* Cystic fibrosis and PCD\n* Neuromuscular diseases and other diseases with reduced airway clearance\n* Severe malacia, diagnosed by bronchoscopy by time of T0.\n* Foreign body inhalation\n* Pneumothorax\n* Pleural effusion (with need of invasive interventions)\n* Bronchopulmonary dysplasia or GA \\\u003C32 weeks\n* Caretaker not able to communicate in Norwegian or English\n* Weight \\\u003C3 kg","0 Days","24 Months",{"count":172,"type":21},200,"1 Year","OBSERVATIONAL","Lower respiratory tract infections (LRTIs) are a significant cause of childhood morbidity and mortality globally, particularly in low-income countries. In Norway, LRTIs is a leading cause of hospitalization among infants, representing a great socioeconomic burden.\n\nBronchiolitis, a viral infection, is the main representation of LRTIs in infants. It affects the small airways, causing breathing- and feeding difficulties. Today, treatment relies on subjective evaluations, lacking objective measures for assessment. This increases the risk of both under- and over treating patients. In the long term, bronchiolitis increases risk of asthma, but it is unknown who the high-risk patients for chronic lung disease are.\n\nLung ultrasonography (LUS) has emerged as a promising tool for assessing bronchiolitis severity and progression of the disease. The investigators will explore its use to improve diagnostic accuracy and treatment decisions, and develop AI-driven scoring tools for novel technology.\n\nAdditionally, tidal breathing flow volume loops (TBFVL) offer a non-invasive method for evaluating airway obstruction in infants, with the potential to assess severity of bronchiolitis, treatment efficacy and post-infection lung function.\n\nIn this project the investigators will combine the use of these modern technologies to improve treatment and follow-up of infants with LRTIs.\n\nThe main aim for this observational study is to assess the utility of lung ultrasonography (LUS) and tidal flow volume loops (TBFVL) in infant lower respiratory tract infections (LRTIs) for individual risk stratification in acute and chronic settings. This aims to refine the management of bronchiolitis, identifying high-risk patients for chronic lung disease to tailor treatment and follow-up protocols.\n\nThe project has three secondary objectives.\n\n1. To assess correlation between LUS and TBFVL findings with clinical score at admission, length of stay, need of respiratory support and ICU admissions.\n2. To assess duration of symptoms following acute bronchiolitis and evaluate the use of LUS and TBFVL in objectively examine post-infectious sequela.\n3. To evaluate the long-term impact of bronchiolitis on lung function through clinical follow-up after a 12 month period.\n\nLower respiratory tract infections (LRTIs) stand as the leading cause of hospitalization, while asthma is the leading cause of chronic lung disease among children in Nordic countries. The project seeks to improve risk stratification and treatment protocols in both acute and chronic settings.\n\nIn the acute setting, the project endeavors to prognosticate individual patient outcomes, thereby individualize treatment and mitigating unnecessary hospital admissions, use of respiratory support and antibiotic administration. Additionally there is potential of more aggressive treatment to selected patients. The study aims to improve the understanding of pathophysiological processes of LRTIs in infants, providing objective metrics to evaluate disease severity and individualize treatment.\n\nThe investigators aim to validate the utility, validity, and simplicity of handheld ultrasound devices as bedside diagnostic tools for this common disease, alongside affirming the value of tidal flow volume loops (TBFVL) in acute and chronic settings to assess airway obstruction in infants. Combining these modern technologies, evaluating affliction of both the parenchyme and the airways will probide a new perspective in treatment of LRTIs. In addition the project will strive to develop novel technology with AI-driven scoring tools of LUS.\n\nFurthermore, the project aims to examine the trajectory of symptoms post-LRTI and facilitate the early identification of patients with high-risk of chronic lung disease. Early detection of asthma and other chronic lung diseases holds the potential to improve outcomes and mitigate the need for hospitalization, thus easing both economic and emotional burdens associated with the disease.\n\nFor caregivers, the lack of information concerning symptom duration and risk of future disease represents a significant knowledge gap. The project aims to address this, by examining post-infection symptom duration and identifying high-risk cohorts predisposed to chronic lung disease. This has the potential to both improve information, personalize follow-up and reduce hospital readmissions.",[177,178,179,180,181,27],"Bronchiolitis Acute","Lower Respiratory Tract and Lung Infections","Pediatric Lung Ultrasound","Tidal Volume","Pediatric Lung Diagnosis",[183,184,185,186],"pediatric","lung ultrasound","lower respiratory tract infections","tidal-flow volume loops","2026-01-26",{"date":189,"type":39},"2026-02-02",{"date":191,"type":39},"2025-12-15",{"date":193,"type":21},"2029-06-30",{"name":195,"class":196},"Helse Møre og Romsdal HF","OTHER_GOV",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":88,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":135},"100533285","phase-2-azithromycin-for-critical-asthma---pediatrics-100533285","NCT06223828","Azithromycin for Critical Asthma - Pediatrics","Azithromycin as Immunomodulation Among Children Hospitalized for Critical Asthma: A Prospective, Open-Label, Non-Randomized, Interventional Study With Parallel Biospecimen Banking","CR-AZI Kids","Inclusion criteria\n\n* Age 3-17 years\n* Admission to the PICU\n* Primary diagnosis of critical asthma\n* Prescription for continuous inhaled beta-agonist therapy and\u002For intravenous (IV) beta-agonist therapy\n* Prescription for intravenous systemic corticosteroids\n\nExclusion criteria\n\n* Critical Congenital Heart Disease Unrepaired\n* Tracheostomy Dependence at Admission\n* Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication\n* Past Medical History of Prolonged QT Syndrome or Arrhythmias\n* Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension",{"count":206,"type":21},100,[208,209],"PHASE2","PHASE3","The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.",[27,212],"Critical Illness","2025-12-16",{"date":215,"type":39},"2025-12-17",{"date":217,"type":39},"2024-04-02",{"date":219,"type":21},"2026-12-31",{"name":221,"class":46},"Johns Hopkins All Children's Hospital",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":231,"conditions":232,"keywords":238,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":135},"100569263","aevicemd-for-detection-of-wheeze-in-pediatric-and-adult-populations-100569263","NCT06691971","AeviceMD for Detection of Wheeze in Pediatric and Adult Populations","A Pilot Study to Assess Aevice Medical Device for Detection of Wheeze in Pediatric and Adult Populations","Inclusion Criteria:\n\n* The subject is willing and\u002For parents\u002Fguardians are able to give informed consent for participation in the study.\n* Male or Female, aged ≥ 3 years.\n* Diagnosed with acute asthma exacerbation by an ED provider.\n\nExclusion Criteria:\n\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the subjects at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study.",{"count":230,"type":21},160,"Respiratory signs and symptoms consisting of wheeze, cough, and breathlessness are obtained in a manual fashion through history taking and physical examination by the healthcare professional. Auscultation of the lung assesses airflow through the trachea-bronchial tree and is helpful in diagnosing various respiratory disorders. AeviceMD is a wearable device that can acquire and process lung sounds, thus assisting in the detection of abnormal lung sounds. The primary objective of this study is to determine if AeviceMD can detect wheeze of pediatrics and adults as accurately as a physician through auscultation. The secondary objective is to investigate if AeviceMD can be used for remote auscultation of breath sounds.",[233,234,235,236,27,237],"Subject Presenting Wheeze","Asthma","Bronchial Disease","Respiratory Tract Diseases","Chronic Respiratory Disease",[239,240,241],"Wheeze","Auscultation","Wearable Medical Device","2025-09-30",{"date":244,"type":39},"2025-10-03",{"date":246,"type":39},"2023-06-29",{"date":248,"type":21},"2026-12",{"name":250,"class":46},"Aevice Health Pte. Ltd.",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":258,"maxAge":88,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":47},"100511892","mechanistic-study-of-inspiratory-training-in-childhood-asthma-mica-100511892","NCT05945355","Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA)","MICA","Inclusion Criteria:\n\n* 6-17 years of age\n* Documented clinician-diagnosed asthma\n* Currently requiring 2 or more controller prescriptions to treat disease (i.e. moderate to severe persistent disease)\n* Either obese (≥95th percentile BMI and less than 170% of the 95th CDC percentile) or have a normal BMI (BMI 5th to 84th CDC percentile)\n\nExclusion Criteria:\n\n* ACT (asthma control test) score \\\u003C17\n* Ever intubated for asthma\n* FEV1 \\\u003C 50% of predicted at enrollment\n* Currently pregnant\n* Legal guardian unable to consent in English or Spanish\n* Any major chronic illness that, in the opinion of the PI, would interfere with participation\n* Younger than 6 years of age","6 Years",{"count":260,"type":21},76,[24],"This is single-center cross-sectional mechanistic study in lean and obese children with moderate-severe asthma, followed by a randomized, SHAM-controlled trial of Inspiratory Training (IT). The primary outcome is to describe the contributions of inspiratory muscle dysfunction (IMD) and Small Airway Dysfunction (SAD) to obesity-related versus non-obesity-related asthma. The study will involve training (IT) for 8 weeks at three intensity levels (SHAM, low and high). Target dose: 150 inspirations three times weekly. The population includes 6 to 17-year-old children with moderate to severe asthma and with a body mass index qualifying as normal habitus (BMI 5th to 84th CDC percentile) or obese habitus (≥95th percentile BMI and less than 170% of the 95th CDC percentile). Participants will be involved for 10 weeks. The investigators will use analysis of covariance (ANCOVA) to estimate and test the difference in mean values of baseline measures between obese and non-obese cohorts. Covariates will include age, sex (male\u002Ffemale), race\u002Fethnicity, baseline asthma severity (NAEPP step 2 vs ≥3), and atopy status",[264,265,266,27],"Asthma in Children","Obesity","Pediatric Obesity","2025-08-18",{"date":269,"type":39},"2025-08-19",{"date":271,"type":39},"2024-08-01",{"date":273,"type":21},"2027-10-30",{"name":275,"class":46},"Duke University",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":283,"maxAge":88,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":135},"100486022","inspiratory-pulmonary-rehabilitation-for-children-with-obesity-and-asthma-100486022","NCT05608668","Inspiratory Pulmonary Rehabilitation for Children With Obesity and Asthma","iPro","Inclusion Criteria:\n\n* Documented informed consent from legal guardian and assent from participant as appropriate.\n* Children 8 to 17 years of age with obesity (BMI ≥ 95th percentile for age and sex) and mild asthma.\n* Participants (or parent\u002Fguardian) must have access to the internet and an approved smart device\u002Fcomputer.\n* Child must have a designated caregiver who expresses a commitment to encourage the participant to complete the study procedures.\n* Participant and legal guardian must speak and read English.\n* Child is currently taking prescription medicine for asthma (Any type of albuterol or inhaled steroid)\n\nExclusion Criteria:\n\n* Prior intubation for asthma\n* Current self-reported pregnancy or planning to become pregnant.\n* Have an FEV1 \\\u003C 50% of predicted at screening\n* History of lung surgery in the past two years,\n* History of pulmonary embolism in the past two years,\n* Any history of recurrent spontaneous pneumothorax, or pneumothorax in the past 12 months\n* Current undiagnosed chest pain,\n* History of inner ear surgery in the past 12 months,\n* Undiagnosed syncopal episodes in the past two years,\n* Progressive neurological or neuromuscular disorders or need for chronic O2 therapy.\n* Inability to complete baseline measurements satisfactorily according to the research coordinator's or PI's judgment.\n* Any condition in the opinion of the PI that would not allow safe conduct of study procedures (including IMR, MIP testing or step-test), such as a physical disability, recent musculoskeletal injury or illness, current and ongoing evaluation for undiagnosed cardiopulmonary or neurologic symptoms","8 Years",{"count":285,"type":21},60,[24],"This is a single-center, randomized, SHAM-controlled, parallel assignment, double-masked,8-week interventional study among children aged 8-17 years (not yet 18 years old) of age with obesity and asthma. (n=60), recruited from Duke Health Center Creekstone, to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity and asthma.\n\nClinic to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity",[266,27],[234,265,290],"Pediatric",{"date":292,"type":39},"2025-08-22",{"date":294,"type":39},"2023-07-27",{"date":102,"type":21},{"name":275,"class":46},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":304,"maxAge":116,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":47},"100516016","the-puerto-rico-asthma-integrated-response-program-pr-air-100516016","NCT05999032","The Puerto Rico Asthma Integrated Response Program (\"PR-AIR\")","PR-AIR","Inclusion Criteria:\n\n1. Children between the ages of 2 and 12 years old\n2. Children must reside in one of the identified catchment areas\n3. Children must meet the screening criteria as having not well controlled or poorly controlled asthma\n\nExclusion Criteria:\n\n1\\. Children with complex medical conditions","2 Years",{"count":306,"type":21},480,[24],"The purpose of this study is to adapt and deliver an evidence-based multi-level intervention to reduce asthma disparities, and that promote and improve population health in the high-burden communities of San Juan, Puerto Rico.\n\nThe Puerto Rico-Asthma Integrated Response Program (PR-AIR) will be implemented and evaluated to address pediatric asthma disparities in San Juan, PR, an area of high asthma burden. This study unfolds in two phases: In Phase 1, the researchers will collaborate with community stakeholders to identify needs, barriers and facilitators of PR-AIR implementation. Phase 2 consists of an evaluation of low-intensity (virtual) and high-intensity (in-person) methods of PR-AIR implementation outcomes using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework and a mixed methods approach.",[27],[123,311,312,313,314,315],"Community intervention program","Hybrid Type III","Effectiveness and implementation","Home-based intervention","School-based intervention","2025-08-14",{"date":318,"type":39},"2025-08-20",{"date":320,"type":39},"2024-12-16",{"date":322,"type":21},"2027-07-31",{"name":324,"class":46},"Rhode Island Hospital",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":258,"maxAge":116,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":135},"100596589","the-airports-air-quality-and-asthma-aaa-study-100596589","NCT07047430","The Airports, Air Quality, and Asthma (AAA) Study","Inclusion Criteria:\n\n* Child is 6-12 years old with a health care provider-diagnosed asthma.\n* Caregiver is comfortable in participating in all study activities in English (communicating with study staff by phone and completing online surveys).\n* Caregiver is familiar with the child's daily asthma health.\n* Residence within 10 miles of Seattle-Tacoma International Airport as determined by zip code\n* Child resides in caregiver's home at least five nights a week on a regular basis and has no plans to move in the next three months.\n\nExclusion Criteria:\n\n* Child has severe asthma at baseline. Severe asthma was defined in consultation with pediatric pulmonologists to be caregiver-reported asthma symptoms every day over the past 14 days and\u002For two or more inpatient hospitalizations for asthma in the past 12 months.\n* Households were excluded if there were multiple individuals within the same household with asthma eligible for the King County CHW Asthma Program or had severe asthma.",{"count":285,"type":21},[24],"For children with asthma, exposure to indoor air pollution increases the risk of a serious asthma exacerbation, which can be life-threatening. Interventions aimed at improving indoor air quality, including use of a portable air cleaner with a high-efficiency particulate air (HEPA) filter, can reduce this risk, but the effectiveness, feasibility and acceptability of HEPA air cleaners varies by setting. In collaboration with a community health worker (CHW) delivered asthma education program, the investigators are conducting a randomized clinical trial to evaluate the effectiveness of HEPA air cleaners to improve indoor air quality and child asthma health in South King County of Washington state, a vulnerable community impacted by air pollution from airports and highway traffic. Key features of the Airports, Air Quality and Asthma (AAA) design include integration of CHWs into study procedures, including CHWs recruited from community-based organizations, into multiple aspects of the trial protocol. The investigators aim to recruit up to N=60 children with asthma randomized into intervention and control groups in a 1:1 ratio, conduct baseline assessments of indoor air quality and airway health, and collect repeated assessments of air quality and airway health during the three-month intervention period and after the trial concludes. Study findings will inform future approaches to integrate HEPA air cleaners into existing CHW asthma education programs in this and similar communities.",[27],[336,337,338,339,340],"air quality","indoor air","portable air cleaner","pediatric asthma","community health workers","2025-06-27",{"date":343,"type":39},"2025-07-02",{"date":345,"type":39},"2024-06-01",{"date":347,"type":21},"2027-06-01",{"name":349,"class":46},"University of Washington",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":18,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":135},"100537502","cohort-multiple-randomized-controlled-trial-in-pediatric-asthma-100537502","NCT06278662","Cohort Multiple Randomized Controlled Trial in Pediatric Asthma","Cohort Multiple Randomized Controlled Trial in Pediatric Asthma: Infrastructure to Assess the Long- and Short-term Effects of (eHealth) Interventions.","CIRCUS","Inclusion Criteria:\n\n* Is 4 to 18 years old\n* Is patient at the children's department at Medisch Spectrum Twente at moment of inclusion\n* Is diagnosed with asthma by a pediatrician following the Global Initiative for Asthma(GINA) guidelines 2022 \\[8\\]:\n\n  \\*Medical history fitting asthma diagnosis:\n* Based on (typical) symptoms: (nighttime) wheezing, dyspnea, coughing (triggered by either viral infections, exercise, allergens or weather changes)\n* (Possibly) supplemented with a family history\u002Fatopy\n\nAND\n\n\\*Spirometry variable expiratory airflow limitation by at least one of these criteria:\n\n* FEV1\u002FFVC reduced compared to lower limit of normal(Z-score ≤ -1.64)\n* Positive bronchodilator responsiveness(increase FEV1\\>12%)\n* Positive Exercise Challenge Test (ECT)(decrease FEV1≥ 13%)\n* Excessive variation in lung function (LF) between tests from different dates (variation FEV1\\>12% pred)\n\nExclusion Criteria:\n\n* The child and\u002For parent(s) has\u002Fhave insufficient command of the Dutch language resulting in the insufficient ability to understand and\u002For answer questions",{"count":359,"type":21},300,[24],"The overarching goal of this study is to optimize pediatric asthma care and to continuously evaluate variations\u002Finnovations of the care (including transformation to remote eHealth care).\n\nPrimary Objectives within cmRCT cohort:\n\n* Provide a framework for multiple randomized (eHealth) interventions for asthmatic children\n* Generate short- and long-term data on Quality of life (QoL), asthma outcomes (asthma control, lung function), quality of care, self-management capacity, healthcare use, and therapy compliance in a representative secondary care pediatric asthma cohort.\n\nSecondary Objectives within cmRCT cohort:\n\n* Evaluate current pediatric asthma care at the Pediatric department of Medisch Spectrum Twente, in order to explore possible improvements for the pediatric asthma care.\n* Compare the short and long-term asthma outcomes between the eHealth care path and the outpatient care path.\n* Compose patient risk profiles that include both personal, clinical and exposome markers and clinical asthma endpoints (for example clinical admission\u002Fexacerbations).",[27],[29,364,365,366],"child","cohort studies","telemedicine","2024-11-22",{"date":369,"type":39},"2024-11-26",{"date":371,"type":39},"2024-04-01",{"date":373,"type":21},"2034-04-01",{"name":375,"class":46},"Mattienne van der Kamp",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":55,"sex":17,"minAge":87,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":386,"conditions":387,"keywords":390,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":135},"100557205","the-impact-of-airway-allergic-diseases-on-childrens-and-parents-quality-of-life-100557205","NCT06535087","The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","The Impact of Airway Allergic Diseases on the Health-related Quality of Life of Children and Their Parents (Caregivers): A Prospective Controlled Study","Inclusion Criteria:\n\n1. Children:\n\n   1. Aged 5-16 years;\n   2. Diagnosed with bronchial asthma, allergic rhinitis, or both (persistent, duration ≥4 weeks) by a respiratory or allergy specialist;\n   3. Guardian has signed the informed consent form;\n   4. Able to understand and complete the questionnaire;\n   5. Outpatients or inpatients at the Pediatrics Department of Renji Hospital in Shanghai.\n2. Parents:\n\n   1. The primary caregiver of the enrolled child;\n   2. Accompanied the child to the hospital on the day of the visit;\n   3. Signed the informed consent form;\n   4. Able to understand and complete the questionnaire.\n\nExclusion Criteria:\n\n1. Children:\n\n   1. Poor compliance;\n   2. Already received specific immunotherapy at another hospital;\n   3. Unable to independently read and complete the questionnaire;\n   4. Lost to follow-up or discontinued treatment.\n2. Parents:\n\n   1. Unwilling to sign the informed consent form;\n   2. Unable to complete the questionnaire due to physical condition or educational level.","16 Years",{"count":385,"type":21},600,"This prospective observational study aims to assess the health-related quality of life (HRQoL) of 200 children (ages 5-16) with bronchial asthma, allergic rhinitis, or both, and their 200 parents, comparing 100 children receiving specific immunotherapy with 100 receiving routine treatment. Using EQ-5D-Y(EuroQol five dimensions questionnaire, youth version), disease-specific scales, and newly developed Chinese versions of EQ-5D-Y and EQ-HWB-S (EuroQol health and well-being questionnaire, short version), the study evaluates HRQoL changes over 1 and 2 years and explores the impact on caregiver burden and spillover effects. A control group of 100 healthy children and their parents will be included. Data collection involves baseline and follow-up surveys, clinical data from medical records, and statistical analyses to compare treatment effects and validate measurement tools.",[27,388,389],"Rhinitis, Allergic","Quality of Life",[391],"pediatric allergic disease, health-related quality of life",{"date":393,"type":39},"2024-08-02",{"date":395,"type":39},"2024-07-20",{"date":397,"type":21},"2027-05-31",{"name":399,"class":46},"Wenjing Zhou"]